TY - JOUR
T1 - Advanced imaging to predict response to chemotherapy in colorectal liver metastases
T2 - a systematic review
AU - Beckers, Rianne C. J.
AU - Lambregts, Doenja M. J.
AU - Lahaye, Max J.
AU - Rao, Sheng-Xiang
AU - Kleinen, Kelly
AU - Grootscholten, Cecile
AU - Beets, Geerard L.
AU - Beets-Tan, Regina G. H.
AU - Maas, Monique
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Background: The assessment of colorectal liver metastases (CRLM) after treatment with chemotherapy is challenging due to morphological and/or functional change without changes in size. The aim of this review was to assess the value of FDG-PET, FDG-PET-CT, CT and MRI in predicting response to chemotherapy in CRLM. Methods: A systematic review was undertaken based on PRISMA statement. PubMed and Embase were searched up to October 2016 for studies on the accuracy of PET, PET-CT, CT and MRI in predicting RECIST or metabolic response to chemotherapy and/or survival in patients with CRLM. Articles evaluating the assessment of response after chemotherapy were excluded. Results: Sixteen studies met the inclusion criteria and were included for further analysis. Study results were available for 6 studies for FDG-PET(-CT), 6 studies for CT and 9 studies for MRI. Generally, features predicting RECIST or metabolic response often predicted shorter survival. The ADC (apparent diffusion coefficient, on MRI) seems to be the most promising predictor of response and survival. In CT-related studies, few attenuation-related parameters and texture features show promising results. In FDG-PET(-CT), findings were ambiguous. Conclusion: Radiological data on the prediction of response to chemotherapy for CRLM is relatively sparse and heterogeneous. Despite that, a promising parameter might be ADC. Second, there seems to be a seemingly counterintuitive correlation between parameters that predict a good response and also predict poor survival.
AB - Background: The assessment of colorectal liver metastases (CRLM) after treatment with chemotherapy is challenging due to morphological and/or functional change without changes in size. The aim of this review was to assess the value of FDG-PET, FDG-PET-CT, CT and MRI in predicting response to chemotherapy in CRLM. Methods: A systematic review was undertaken based on PRISMA statement. PubMed and Embase were searched up to October 2016 for studies on the accuracy of PET, PET-CT, CT and MRI in predicting RECIST or metabolic response to chemotherapy and/or survival in patients with CRLM. Articles evaluating the assessment of response after chemotherapy were excluded. Results: Sixteen studies met the inclusion criteria and were included for further analysis. Study results were available for 6 studies for FDG-PET(-CT), 6 studies for CT and 9 studies for MRI. Generally, features predicting RECIST or metabolic response often predicted shorter survival. The ADC (apparent diffusion coefficient, on MRI) seems to be the most promising predictor of response and survival. In CT-related studies, few attenuation-related parameters and texture features show promising results. In FDG-PET(-CT), findings were ambiguous. Conclusion: Radiological data on the prediction of response to chemotherapy for CRLM is relatively sparse and heterogeneous. Despite that, a promising parameter might be ADC. Second, there seems to be a seemingly counterintuitive correlation between parameters that predict a good response and also predict poor survival.
KW - POSITRON-EMISSION-TOMOGRAPHY
KW - APPARENT DIFFUSION-COEFFICIENT
KW - CT TEXTURE ANALYSIS
KW - FDG-PET
KW - PREOPERATIVE CHEMOTHERAPY
KW - HEPATIC METASTASES
KW - CERVICAL-CANCER
KW - TUMOR RESPONSE
KW - 1ST-LINE CHEMOTHERAPY
KW - ENHANCED MRI
U2 - 10.1016/j.hpb.2017.10.013
DO - 10.1016/j.hpb.2017.10.013
M3 - (Systematic) Review article
C2 - 29196021
VL - 20
SP - 120
EP - 127
JO - HPB
JF - HPB
SN - 1365-182X
IS - 2
ER -